McGuire Investment Group LLC Buys Shares of 117,102 SPDR S&P Biotech ETF (XBI)

McGuire Investment Group LLC bought a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 117,102 shares of the exchange traded fund’s stock, valued at approximately $11,227,000. SPDR S&P Biotech ETF accounts for 3.7% of McGuire Investment Group LLC’s portfolio, making the stock its 7th largest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of XBI. Howard Capital Management increased its position in shares of SPDR S&P Biotech ETF by 2.5% during the 3rd quarter. Howard Capital Management now owns 154,827 shares of the exchange traded fund’s stock valued at $14,843,000 after purchasing an additional 3,780 shares during the last quarter. Natixis increased its position in shares of SPDR S&P Biotech ETF by 5.5% during the 2nd quarter. Natixis now owns 49,498 shares of the exchange traded fund’s stock valued at $4,712,000 after purchasing an additional 2,594 shares during the last quarter. Leonetti & Associates LLC increased its position in shares of SPDR S&P Biotech ETF by 40.5% during the 2nd quarter. Leonetti & Associates LLC now owns 139,225 shares of the exchange traded fund’s stock valued at $13,253,000 after purchasing an additional 40,150 shares during the last quarter. Adirondack Trust Co. increased its position in shares of SPDR S&P Biotech ETF by 73.6% during the 3rd quarter. Adirondack Trust Co. now owns 5,895 shares of the exchange traded fund’s stock valued at $565,000 after purchasing an additional 2,500 shares during the last quarter. Finally, Chatham Capital Group Inc. increased its position in shares of SPDR S&P Biotech ETF by 2.0% during the 3rd quarter. Chatham Capital Group Inc. now owns 73,485 shares of the exchange traded fund’s stock valued at $7,045,000 after purchasing an additional 1,450 shares during the last quarter.

NYSEARCA XBI opened at $77.28 on Wednesday. SPDR S&P Biotech ETF has a 52 week low of $76.37 and a 52 week high of $101.55.

COPYRIGHT VIOLATION NOTICE: This article was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.wkrb13.com/2018/11/14/mcguire-investment-group-llc-buys-shares-of-117102-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Read More: Trading Strategy Methods for Individual Investors

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply